Home » Topics » Regulatory » EMA

EMA
RSS

Exondys receives negative CHMP opinion

June 4, 2018

Tegsedi receives positive opinion in Europe

June 4, 2018

EMA validates MAA for Inbrija

May 30, 2018

EMA accepts European filing for edaravone for ALS

May 29, 2018

European designation decisions for BioCryst's BCX-7353 for HAE

May 25, 2018

EMA approves Lynparza tablets for the treatment of platinum-sensitive relapsed ovarian cancer

May 9, 2018

EMA gives positive scientific advice on development plan and regulatory pathway for AM-111

May 8, 2018

EMA validates type II variation application for Opdivo plus Yervoy in first-line NSCLC

May 4, 2018

EMA approves Alpivab for the treatment of influenza

May 3, 2018

European approval recommended for Perjeta as post-surgery treatment of HER2-positive breast cancer

May 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...